Exosomes in Skincare: The Claims and the Evidence

Exosomes are extracellular vesicles, tiny lipid-bilayer packages that cells release to carry proteins and RNA. In aesthetics they are almost always used inside a clinic, applied right after a procedure that has already opened the skin. Outside that setting the human evidence is thin, and the term itself is discouraged by the field's own consensus guideline.

What are exosomes, exactly?

Start with the parent category. The International Society for Extracellular Vesicles defines an extracellular vesicle by three criteria (MISEV2023). It is released from a cell. It is delimited by a lipid bilayer. It cannot replicate on its own.

An exosome is one subtype of that category. The name refers to how the vesicle was built, not how big it is. Exosomes form inside the endosomal system before the cell releases them.

Size gets quoted loosely across the industry. A 2020 review in Science puts the average exosome diameter at roughly 100 nanometers (Kalluri and LeBleu). MISEV2023 notes that small extracellular vesicles are often described as under 200 nanometers in diameter. It adds that measured diameter is related to the specific characterization method used.

Product copy usually quotes a tighter window than the published literature supports. Read any single number on a label as an industry convention, not as a measurement of what sits in a particular bottle.

The cargo is what draws interest. Exosomes carry nucleic acids, proteins, lipids, amino acids, and metabolites that reflect the cell of origin. That is why they are studied as messengers between cells.

Why researchers avoid the word "exosome"

This is the part the category rarely mentions. The consensus guideline for the whole field lists "exosome" as a term to be used with care.

MISEV2023 marks the word as "Discouraged unless subcellular origin can be demonstrated." The reasoning is practical. Proving endosomal origin is difficult. So most preparations are likely a broad population of vesicles, not exosomes specifically.

The same document says ISEV discourages biogenesis-based terms unless that population is specifically separated and characterized. It also flags a second problem: separating true vesicles from non-vesicular extracellular particles that ride along in the same preparation.

So a jar labeled exosome is making a manufacturing claim. Unless the maker publishes isolation and characterization data, the label describes an intention, not a verified structure.

What does the clinical research on exosomes actually show?

There is real human work. It is small, mostly split-face, and almost always paired with an in-clinic device. None of the studies below involve re:tones products.

Study	Design	People	How it was applied	Reported outcome
Acne scars, 2020	12 weeks, double-blind, randomized, split-face	25	Adipose stem cell exosome gel after fractional CO2 laser, control gel on the other side	ECCA scar score fell 32.5% on the exosome side vs 19.9% on control, p < 0.01
Topical platelet exosomes, 2022	6 weeks, single-arm, non-randomized, no control group	Not stated in abstract	Topical serum plus a standardized skin care regimen	Skin health score improved by 224.2 ± 112.8, P ≤ 0.0001
Facial aging, 2023	12 weeks, prospective, randomized, split-face	28	Adipose stem cell exosome solution with microneedling, saline with microneedling on the other side	Global Aesthetic Improvement Scale favored the exosome side, p = 0.005
Exosomes vs PRP, 2025	Investigator-blinded, split-face, non-inferiority	Not stated in abstract	Three radiofrequency microneedling sessions, exosomes on one side, platelet-rich plasma on the other	Exosomes and PRP improved wrinkling, dyschromia, erythema, texture and overall appearance equally; histology showed increased collagen I and glycosaminoglycans, without significant differences between arms

Read the second row carefully. A single-arm study with no control cannot separate the serum from the regimen applied alongside it. Nor from six weeks of consistent use.

Read the fourth row carefully too. Non-inferiority to platelet-rich plasma is a comparison between two treatments, not a demonstration that either one beat doing nothing.

The review literature is similarly cautious about how much human data exists. A 2025 review of exosomes for hair loss searched three databases and included 48 studies, 25 of which were clinical trials (Queen and Avram). Nine of those studies were relevant to alopecia, covering 125 patients who received an exosome treatment for hair loss. Those nine are the hair loss subset, so they do not measure how much skin care evidence exists, but the authors note that very limited data are available on safety and efficacy in human subjects.

Can exosomes cross intact skin?

This is the question that decides whether a home exosome serum makes sense. Two separate lines of published evidence bear on it.

The first is molecular weight. Bos and Meinardi proposed the widely cited 500 Dalton rule (Bos and Meinardi, 2000). They argued that a compound must be under 500 Daltons to be absorbed through the corneal layer. Their supporting arguments were that common contact allergens, common topical dermatologic drugs, and known transdermal delivery agents all sit under that threshold.

The second is particle size. Researchers tracked fluorescently tagged polystyrene nanoparticles at 20 and 200 nanometers across full-thickness human skin samples (Döge and colleagues, 2018). The particles preferentially accumulated in the stratum corneum and in the upper part of vellus hair follicles. Deeper penetration happened, but the authors described it as a rare event observed at sites of high focal particle aggregations.

An exosome is not a 500 Dalton molecule. It is an intact vesicle roughly the size of the nanoparticles in that study. The barrier physics do not favor it. Our guide to transdermal delivery covers why the corneal layer is so effective at this.

That does not make a topical exosome product useless. Vesicle preparations carry lipids and proteins that can behave like any other cosmetic ingredient on the surface. It does mean that claims about vesicles reaching living tissue through unbroken skin are not supported by the penetration literature.

Why exosome protocols are almost always in-clinic

Once you understand the barrier problem, the shape of the research makes sense. The clinical studies do not rely on topical application alone. They open the skin first.

One group labeled umbilical cord stem cell vesicles with a fluorescent dye (Wang and colleagues, 2023). They then compared penetration routes in an animal model. Vesicles reached the deep dermis under microneedles, under a 1565 nm non-ablative fractional laser, and under a plasma device. In that animal model the delivery came from the clinical device, not from the vesicle.

A 2025 review of exosomes in skin aging lists microneedling and hydrogels among the delivery systems used to improve penetration (Liang and colleagues). The same review names scalability of production, standardization of purification, and unknown long-term effects as open challenges.

Two cautions follow. First, those protocols run under a clinician who controls sterility, depth, and product sourcing. That is a different situation from anything a consumer can set up at home. Second, the Wang study also ran a clinical arm in 60 patients with melasma, split into four groups, each receiving four treatments at one-month intervals in a hospital department.

Melasma is a medical condition. It is diagnosed and managed by a board-certified dermatologist, not chosen from a product page. Nothing in that trial describes a routine you can assemble yourself.

Do not pair an unstandardized biological product with a home device. Sterility, particle content, and endotoxin load are not verifiable by the buyer. For the difference in setting, see at-home vs professional microneedling, and for background on the tool itself, start with what microneedling is.

How are exosomes regulated in the United States?

The category sits in an awkward gap, and the gap is worth understanding before you spend money.

US law defines a cosmetic by intended use. Under 21 U.S.C. 321(i), a cosmetic is an article applied to the body for cleansing, beautifying, promoting attractiveness, or altering the appearance. A product marketed to change how the body works is being sold as a different kind of article.

Human cell and tissue products face a separate framework. Under 21 CFR 1271.10, such a product is regulated solely under section 361 of the Public Health Service Act only if it meets all four listed criteria. It must be minimally manipulated. It must be intended for homologous use only. Its manufacture must not involve combining the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent that raises no new clinical safety concerns. And it must either lack a systemic effect and not depend on the metabolic activity of living cells for its primary function, or else fall into the autologous, close-blood-relative, or reproductive-use carve-outs. Isolating vesicles from cultured cells is a poor fit for that set.

A 2023 review in Regenerative Medicine stated it directly (Vyas and colleagues). There were no US FDA-approved exosome products on the market for medical indications. The same review said topical exosomes, though variable in source and isolation method, are generally considered safe in humans on intact skin. It also said the published literature gives no clear consensus on long-term use.

Safety is not purely theoretical. The 2025 hair loss review reported that side effects were rare in the alopecia studies, but that at least 10 serious adverse events have been reported in the broader field of dermatology (Dermatologic Surgery, 2025). It called for consistent manufacturing standards and regulatory oversight.

A 2023 analysis of the commercial landscape put the manufacturing issue plainly. Multiple commercial vesicle sources are marketed for topical cosmetic use (Davies and colleagues). Questions about product standardization, potency, and regulation remain unresolved.

What about plant exosomes and exosome-like nanoparticles?

A newer wave of products cites plant-derived exosome-like nanoparticles. These are a different thing from human or animal cell vesicles, and the evidence is at an earlier stage.

One study isolated ginseng root-derived exosome-like nanoparticles (Choi and colleagues, 2024). They were tested on cultured HaCaT keratinocytes exposed to UVB and hydrogen peroxide. The nanoparticles reduced reactive oxygen species and lowered expression of several aging-related and pro-inflammatory genes in those cells.

That is cell culture. Cells in a dish have no stratum corneum, so the delivery question the whole category turns on was never tested. Findings like this justify further research. They do not describe what happens on a face.

How exosomes compare to other regenerative ingredient stories

Exosomes are the third recent ingredient story built on a delivery promise. The three are worth separating.

Peptides are short chains of amino acids. They are small molecules, they are chemically defined, and a given peptide can be synthesized to the same specification every time. Whether a specific peptide penetrates depends on that peptide.

PDRN and salmon DNA sit in the middle. They are polymers, not vesicles, and like exosomes their clinical literature is dominated by injected and post-procedure use rather than topical application.

Exosomes are the largest and least defined of the three. A batch is a population of particles, not a molecule. Two products carrying the same word may share very little. That variability is the field's own stated obstacle, not a critic's complaint.

Our science overview explains how we read ingredient literature and why we separate what a study measured from what a label implies.

How to read an exosome serum label

If you are still curious, these are the questions worth asking a brand.

• What cell type is the source, and is it named on the product page?
• What is the particle count per milliliter, and by which measurement method?
• Is characterization data published, or only the word exosome?
• Does the brand claim the vesicles reach living skin through an intact barrier? That claim is not supported by the penetration literature.
• Is the product shipped and stored cold, and what is the stated shelf life once opened?
• Is it sold bundled with a home device? Treat that pairing as a reason for caution.

A brand that can answer the first three is operating at a different level from one that cannot. Most cannot.

The honest summary

Exosomes are a legitimate area of biology with a serious research community behind them. That community publishes consensus documents telling its own members to be careful with the word.

The human aesthetic evidence exists, and it is small, short, and built around in-clinic devices that breach the barrier first. The topical-only evidence is weaker still, and the most cited topical study had no control group.

None of that is a reason to dismiss the science. It is a reason to be skeptical of a serum that borrows the science's vocabulary without its methods.

FAQ

Do exosome serums work?

The published human studies that showed benefit almost all applied exosomes immediately after microneedling or laser treatment. The one prominent topical-only study was single-arm with no control group. It cannot separate the serum from the routine used alongside it. A 2023 review describes topical exosomes as generally considered safe on intact skin, but topical-only efficacy remains poorly established.

What are exosomes in skincare?

They are extracellular vesicles isolated from cultured cells, most often mesenchymal or adipose-derived stem cells, or from platelets. Each vesicle is a lipid-bilayer package holding proteins, lipids, and RNA. Average exosome diameter is around 100 nanometers. In a finished product they are a population of particles rather than a single defined molecule.

What happens during an exosome facial?

Protocols vary by clinic, and there is no standardized procedure. Published studies typically apply a vesicle solution right after microneedling, fractional laser, or radiofrequency microneedling, so the device creates the delivery route. Because sourcing and manufacturing are not standardized across suppliers, ask the provider what product they use and where it comes from.

Are exosome skincare products FDA approved?

A 2023 review in Regenerative Medicine reported no US FDA-approved exosome products on the market for medical indications. US law defines a cosmetic by intended use under 21 U.S.C. 321(i), covering articles applied to beautify or alter appearance. Products marketed as doing more than that are making claims that belong to a different regulatory category.

Are exosomes safe?

A 2023 review in Regenerative Medicine describes topical exosomes on intact skin as generally considered safe, and the 2023 split-face facial aging trial reported no serious adverse events. A 2025 hair loss review found side effects rare in alopecia studies, but noted at least 10 serious adverse events reported in the broader field of dermatology. Injected and post-procedure use carries risks topical use does not.

Can I use an exosome serum after microneedling at home?

No, and this is the clearest recommendation in this article. Every published protocol runs under a clinician who controls sterility, depth, and product sourcing. Home users cannot verify particle content, endotoxin load, or sterility of an unstandardized biological product. Opening the skin and then applying one is a route to infection, not results.